PepGen prices $80.1M common stock offering of 7.53M shares at $10.635 per share

PepGen Inc.

Gross proceeds ~$80.1M; net proceeds ~$76.4M after underwriting discounts and expenses.
Offering led by RA Capital Management; 11 institutional investors including Adage, Frazier, Janus.
Net proceeds to fund R&D and clinical development of oligonucleotide therapies; cash runway into 2026.
Offering expected to close February 9, 2024; Leerink Partners sole bookrunner.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

PepGen Inc. entered into Underwriting Agreement with Leerink Partners LLC valued at Underwriting Agreement for 7,530,000 shares of common stock at $10.635 per share, net proceeds appro (effective 2024-02-06).

Action: entry
Agreement: underwriting
Counterparty: Leerink Partners LLC
Value: Underwriting Agreement for 7,530,000 shares of common stock at $10.635 per share, net proceeds appro
Effective: 2024-02-06

Exact text from the filing

On February 6, 2024, PepGen Inc. (the " Company ") entered into an underwriting agreement (the " Underwriting Agreement ") with Leerink Partners LLC, as underwriter, pursuant to which the Company agreed to issue and sell an aggregate of 7,530,000 shares (the " Shares ") of its common stock, par value $0.0001 per share (the " Common Stock "), at a price to the public of $10.635 per share.

View on SEC.gov

622 material agreements filed in the last 30 days. Browse all material agreements →

PepGen Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-025921

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.